

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : WILLEM FERDINAND NIEUWENHUIZEN, ET AL.
Application No. : 10/592,994
Deposit date : September 15, 2006
Confirmation No. : 8473
For : THE USE OF SPHINGOLIPIDS IN THE TREATMENT AND
PREVENTION OF TYPE 2 DIABETES MELLITUS, INSULIN
RESISTANCE AND METABOLIC SYNDROME
Attorney's Docket : VER-209XX

TC Art Unit:

*
I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 on _____.

By: _____

Charles L. Gagnebin III
Registration No.25,467
Attorney for Applicant(s)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the
enclosed references listed on the attached copy of PTO Form #1449. The
paragraph(s) marked below are applicable to this Information Disclosure
Statement.

[] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached
Information Disclosure Statement is being filed within three
months of the filing date of the above identified national
application or within three months of the date of entry of the
national stage as set forth in 37 C.F.R. § 1.491 of the above
identified application. Accordingly, applicant(s) believes that
no fee or statement under 37 C.F.R. § 1.97(e) is required.

Express Mail Number

EV 560127926 US

Application No.: 10/592,994
Deposit date: September 15, 2006
Confirmation No.: 8473
TC Art Unit:

- [X] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
[] a statement under 37 CFR § 1.97(e); or
[] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- [] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- [] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- [] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of

Application No.: 10/592,994
Deposit date: September 15, 2006
Confirmation No.: 8473
TC Art Unit:

information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Where the status of the application has changed, unknown to the applicant, such that the boxes checked are no longer applicable, the Commissioner is authorized to accept this submission with any additional fees required by that change charged to Deposit Account No. 23-0804.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made. The filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited herewith is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that Applicant(s) is(are) unable to provide an affidavit under 37 CFR §1.131 swearing back of such information.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.


Copies of the foreign references and/or non-patent references cited in the International Search Report (ISR) and our IDS at filing are now enclosed.

Application No.: 10/592,994
Deposit date: September 15, 2006
Confirmation No.: 8473
TC Art Unit:

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

WILLEM FERDINAND NIEUWENHUIZEN ET AL.

By: 

Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290
Telecopier: (617) 451-0313

CLG/mc/349762.1
Enclosure

Dated: March 23, 2007

(REV. 05/03)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.	APPLICATION NO.	
		VER-209XX	10/592,994	
		APPLICANT: Willem Ferdinand Nieuwenhuizen, et al.		
		DEPOSIT DATE September 15, 2006	TC ART UNIT	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION/ ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	JP 2001 213858 A Abstract*	08-2001	Japan			X*
	WO 03/096983	11-2003	WIPO			X
	WO 01/60807	08-2001	WIPO			X
	EP 0 988 860	03-2000	European Pat. Off.			X
	WO 01/72701	10-2001	WIPO			X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	VAN VELDHOVEN PAUL P ET AL: "Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?" ; CELLULAR SIGNALLING, vol. 12, no. 7, July 2000 (2000-07), pages 475-479, page 477, column 2, lines 13-29
	TURINSKY J ET AL: "EFFECT OF SPHINGOID BASES ON BASAL AND INSULIN-INDUCED GLUCOSE UPTAKE BY SKELETAL MUSCLE", JOURNAL OF CELL BIOLOGY, vol. 115, no. 3 PART 2, 1991, page 222A; & ABSTRACTS OF PAPERS PRESENTED AT THE THIRTY-FIRST ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BI
	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2002 (2002-03), MEI JIE ET AL: "C2-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes", Database accession no. PREV200200229126 cited in the application, & DIABETES, vol. 51, no. 3, March 2002 (2002-03), pages 631-637.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CLG/mc/349763.1 (refs encl)

REFERENCES were cited in ISR of PCT/NL2005/000193